MEN1 and leukemia: The promising preclinical results with Menin inhibitors have led to the initiation of first‐in‐human clinical trials for revumenib, ziftomenib, and JNJ‐75276617 in adults with relapsed/refractory (R/R) leukemia featuring KMT2A‐r and NPM−1 mutations.